As global health threats continue to evolve rapidly, pharmaceutical leaders face mounting pressure to design development programs that can withstand volatility. From pandemics to geopolitical unrest ...

Company to Prioritize Clinical Development of Tacrolimus Inhalation Powder (TFF TAC) based on Positive Phase 2 Data, the Potential to Address a Significant Unmet Need in Lung Transplant Medicine and ...

Approximately 70 million people that live, work or vacation in areas of the U.S. in which Lyme disease is endemic could potentially benefit from pre-exposure prophylaxis TNX-4800 was studied in a ...

The Department of Health and Human Services, Office of Inspector General (“OIG”) recently released a favorable advisory opinion, OIG Advisory Opinion No. 24-11 (the “Opinion”), to a pharmaceutical ...

The Leidos team’s Next-Generation Medical Countermeasures (MCMs) Successfully Formulated with Company’s Proprietary Thin Film Freezing Technology MCM Candidates Demonstrated Chemical and Biological ...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) released results from a neurotoxicity study of Ketamir-2, its novel oral NMDA receptor antagonist, on Tuesday. The U.S. Food and Drug Administration (FDA) ...

* Says Celgene will pay Agios an $8 million designation fee for MTAP pathway program * Agios Pharmaceuticals Inc - Celgene will have an opt-in right on program up through Phase 1 dose escalation for ...

VCU's unique pharmaceutical engineering program helped attract Eli Lilly's $5 billion investment to Virginia, creating a specialized workforce pipeline for advanced cancer treatment manufacturing.

The latest update is out from Daito Pharmaceutical Co., Ltd. ( ($JP:4577) ). Daito Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company ...

(MENAFN- GlobeNewsWire - Nasdaq) Exploring clinical development plan options including a controlled human infection model (CHIM) and a Phase 2/3 adaptive field study Expect to have investigational ...